Green Cross, a South Korean biopharma, signed a MOU earlier this month with China’s Guizhou provincial government to build a cell therapy manufacturing and distributing center in Guizhou, a southwestern province of China. The company offers a portfolio of approved and investigational cell therapy projects including T cell, NK cell, dendritic cell and stem cells. As a reason for the investment, Green Cross cited the increasing global interest in cell therapy treatments for serious diseases.
Help employers find you! Check out all the jobs and post your resume.
